Rebecca C Fitzgerald

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4040048/publications.pdf

Version: 2024-02-01

212 papers	15,782 citations	17440 63 h-index	20961 115 g-index
225 all docs	225 docs citations	225 times ranked	15346 citing authors

#	Article	IF	Citations
1	Utility and Cost-Effectiveness of a Nonendoscopic Approach to Barrettâ€™s Esophagus Surveillance After Endoscopic Therapy. Clinical Gastroenterology and Hepatology, 2022, 20, e51-e63.	4.4	2
2	Cytosponge-TFF3 Testing can Detect Precancerous Mucosal Changes of the Stomach. Clinical Gastroenterology and Hepatology, 2022, 20, 1411-1412.	4.4	2
3	Post-endoscopy Esophageal Neoplasia in Barrettâ€™s Esophagus: Consensus Statements From an International Expert Panel. Gastroenterology, 2022, 162, 366-372.	1.3	12
4	Limitations of Heartburn and Other Societiesâ€™ Criteria in Barrettâ€™s Screening for Detecting De Novo Esophageal Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2022, 20, 1709-1718.	4.4	17
5	Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot. Lancet Oncology, The, 2022, 23, 270-278.	10.7	28
6	Computational pathology aids derivation of microRNA biomarker signals from Cytosponge samples. EBioMedicine, 2022, 76, 103814.	6.1	0
7	Multi-omic cross-sectional cohort study of pre-malignant Barrettâ€™s esophagus reveals early structural variation and retrotransposon activity. Nature Communications, 2022, 13, 1407.	12.8	15
8	The utility of <scp>P53</scp> immunohistochemistry in the diagnosis of Barrett's oesophagus with indefinite for dysplasia. Histopathology, 2022, 80, 1081-1090.	2.9	5
9	Early detection of cancer. Science, 2022, 375, eaay9040.	12.6	291
10	Patient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trial. BMJ Open, 2022, 12, e054258.	1.9	6
11	Rearrangement processes and structural variations show evidence of selection in oesophageal adenocarcinomas. Communications Biology, 2022, 5, 335.	4.4	8
12	Impact of Barrett oesophagus diagnoses and endoscopies on oesophageal cancer survival in the UK: A cohort study. Cancer Medicine, 2022, 11, 1160-1171.	2.8	3
13	The future of early cancer detection. Nature Medicine, 2022, 28, 666-677.	30.7	92
14	Deciphering the Immune Complexity in Esophageal Adenocarcinoma and Pre-Cancerous Lesions With Sequential Multiplex Immunohistochemistry and Sparse Subspace Clustering Approach. Frontiers in Immunology, 2022, 13, .	4.8	6
15	Multiparametric High-Content Cell Painting Identifies Copper Ionophores as Selective Modulators of Esophageal Cancer Phenotypes. ACS Chemical Biology, 2022, 17, 1876-1889.	3.4	11
16	Quantification of TFF3 expression from a non-endoscopic device predicts clinically relevant Barrett's oesophagus by machine learning. EBioMedicine, 2022, 82, 104160.	6.1	2
17	Minimally invasive esophageal sponge cytology sampling is feasible in a Tanzanian community setting. International Journal of Cancer, 2021, 148, 1208-1218.	5.1	13
18	Single-bite versus double-bite technique for mapping biopsies during endoscopic surveillance for hereditary diffuse gastric cancer: a single-center, randomized trial. Endoscopy, 2021, 53, 246-253.	1.8	5

#	Article	IF	Citations
19	Hereditary Diffuse Gastric Cancer: Approaches to Screening, Surveillance, and Treatment. Annual Review of Medicine, 2021, 72, 263-280.	12.2	15
20	Progress in Screening for Barrettâ€™s Esophagus. Gastrointestinal Endoscopy Clinics of North America, 2021, 31, 43-58.	1.4	7
21	Practical early cancer detection: distinguishing stable from unstable genomes in pre-cancerous tissues. British Journal of Cancer, 2021, 124, 683-685.	6.4	1
22	Randomized Controlled Trial of the Gastrin/CCK2 Receptor Antagonist Netazepide in Patients with Barrett's Esophagus. Cancer Prevention Research, 2021, 14, 675-682.	1.5	5
23	Screening for Barrettâ€™s Oesophagus: Are We Ready for it?. Current Treatment Options in Gastroenterology, 2021, 19, 321-336.	0.8	5
24	Surveillance and Endoscopic Recognition of Gastric Intestinal Metaplasia and Atrophic Gastritis: A Retrospective Cohort Study in Two Academic Centers. , 2021, 53, .		0
25	Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma. Nature Communications, 2021, 12, 1454.	12.8	20
26	Evidence that polyploidy in esophageal adenocarcinoma originates from mitotic slippage caused by defective chromosome attachments. Cell Death and Differentiation, 2021, 28, 2179-2193.	11.2	7
27	Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling. Annals of Oncology, 2021, 32, 522-532.	1.2	53
28	Triage-driven diagnosis of Barrettâ€™s esophagus for early detection of esophageal adenocarcinoma using deep learning. Nature Medicine, 2021, 27, 833-841.	30.7	65
29	Chromosomal copy number heterogeneity predicts survival rates across cancers. Nature Communications, 2021, 12, 3188.	12.8	43
30	Economic evaluation of CytospongeÂ®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data. EClinicalMedicine, 2021, 37, 100969.	7.1	5
31	Genomic instability signals offer diagnostic possibility in early cancer detection. Trends in Genetics, 2021, 37, 966-972.	6.7	11
32	Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma. Cancers, 2021, 13, 3394.	3.7	9
33	Serial Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Esophageal Adenocarcinoma Patients Following Resection. Gastroenterology, 2021, 161, 1705-1708.e2.	1.3	8
34	The risk of neoplasia in patients with Barrett's esophagus indefinite for dysplasia: a multicenter cohort study. Gastrointestinal Endoscopy, 2021, 94, 263-270.e2.	1.0	9
35	Molecular phenotyping reveals the identity of Barrettâ€™s esophagus and its malignant transition. Science, 2021, 373, 760-767.	12.6	99
36	Extensive phylogenies of human development inferred from somatic mutations. Nature, 2021, 597, 387-392.	27.8	87

#	Article	IF	Citations
37	The mutational landscape of human somatic and germline cells. Nature, 2021, 597, 381-386.	27.8	180
38	Evolution and progression of Barrettâ€™s oesophagus to oesophageal cancer. Nature Reviews Cancer, 2021, 21, 731-741.	28.4	32
39	Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence. Nature Genetics, 2021, 53, 1553-1563.	21.4	71
40	OFR-5â€…Surveillance and endoscopic recognition of gastric intestinal metaplasia and atrophic gastritis. , 2021, , .		0
41	Alterations in the Ca2+ toolkit in oesophageal adenocarcinoma. Exploration of Targeted Anti-tumor Therapy, 2021, 2, .	0.8	1
42	Comparison of Phenotypes and Risk Factors for Esophageal Adenocarcinoma at Present vs Prior Decades. Clinical Gastroenterology and Hepatology, 2020, 18, 2710-2716.e1.	4.4	5
43	Big data is crucial to the early detection of cancer. Nature Medicine, 2020, 26, 19-20.	30.7	19
44	scRNA-seq assessment of the human lung, spleen, and esophagus tissue stability after cold preservation. Genome Biology, 2020, 21, 1.	8.8	572
45	Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma. Nature Genetics, 2020, 52, 74-83.	21.4	53
46	Role of TFF3 as an adjunct in the diagnosis of Barrett's esophagus using a minimally invasive esophageal sampling deviceâ€”The Cytosponge^{TM}. Diagnostic Cytopathology, 2020, 48, 253-264.	1.0	22
47	Development and validation of a risk prediction model to diagnose Barrett's oesophagus (MARK-BE): a case-control machine learning approach. The Lancet Digital Health, 2020, 2, e37-e48.	12.3	19
48	Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrettâ€™s Esophagus. Clinical Gastroenterology and Hepatology, 2020, 18, 2701-2709.e3.	4.4	12
49	Time to Challenge Current Strategies for Detection of Barrettâ€™s Esophagus and Esophageal Adenocarcinoma. Digestive Diseases and Sciences, 2020, 65, 18-21.	2.3	4
50	Use of Cytosponge as a triaging tool to upper gastrointestinal endoscopy during the COVID-19 pandemic. The Lancet Gastroenterology and Hepatology, 2020, 5, 805-806.	8.1	13
51	Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure. Nature Genetics, 2020, 52, 1178-1188.	21.4	79
52	The utility of a methylation panel in the assessment of clinical response to radiofrequency ablation for Barrett's esophagus. EBioMedicine, 2020, 58, 102877.	6.1	1
53	Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. Lancet, The, 2020, 396, 333-344.	13.7	143
54	Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncology, The, 2020, 21, e386-e397.	10.7	237

#	Article	IF	Citations
55	Endoscopic tumour morphology impacts survival in adenocarcinoma of the oesophagus. European Journal of Surgical Oncology, 2020, 46, 2257-2261.	1.0	1
56	Genomic copy number predicts esophageal cancer years before transformation. Nature Medicine, 2020, 26, 1726-1732.	30.7	86
57	Sex-Specific Genetic Associations for Barrettâ€™s Esophagus and Esophageal Adenocarcinoma. Gastroenterology, 2020, 159, 2065-2076.e1.	1.3	16
58	Shared Genetic Etiology of Obesity-Related Traits and Barrett's Esophagus/Adenocarcinoma: Insights from Genome-Wide Association Studies. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 427-433.	2.5	7
59	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports, 2020, 31, 107550.	6.4	51
60	The mutREAD method detects mutational signatures from low quantities of cancer DNA. Nature Communications, 2020, 11, 3166.	12.8	9
61	Aneuploidy in targeted endoscopic biopsies outperforms other tissue biomarkers in the prediction of histologic progression of Barrett's oesophagus: A multi-centre prospective cohort study. EBioMedicine, 2020, 56, 102765.	6.1	19
62	Identification of Subtypes of Barrettâ€™s Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data. Gastroenterology, 2020, 158, 1682-1697.e1.	1.3	58
63	Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nature Genetics, 2020, 52, 306-319.	21.4	275
64	Machine learning to predict early recurrence after oesophageal cancer surgery. British Journal of Surgery, 2020, 107, 1042-1052.	0.3	35
65	Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining. , 2019, 203, 107395.		76
66	Patient-specific cancer genes contribute to recurrently perturbed pathways and establish therapeutic vulnerabilities in esophageal adenocarcinoma. Nature Communications, 2019, 10, 3101.	12.8	34
67	High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrettâ€™s Esophagus via Interleukin 8 and Alterations to the Gut Microbiome. Gastroenterology, 2019, 157, 492-506.e2.	1.3	100
68	Gastroesophageal reflux GWAS identifies risk loci that also associate with subsequent severe esophageal diseases. Nature Communications, 2019, 10, 4219.	12.8	58
69	Early detection and therapeutics. Molecular Oncology, 2019, 13, 599-613.	4.6	17
70	Barrett oesophagus. Nature Reviews Disease Primers, 2019, 5, 35.	30.5	98
71	A clinically translatable hyperspectral endoscopy (HySE) system for imaging the gastrointestinal tract. Nature Communications, 2019, 10, 1902.	12.8	75
72	Ingested asbestos in filtered beer, in addition to occupational exposure, as a causative factor in oesophageal adenocarcinoma. British Journal of Cancer, 2019, 120, 1099-1104.	6.4	5

#	Article	IF	Citations
73	Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction. International Journal of Cancer, 2019, 145, 3389-3401.	5.1	17
74	Will a Proton Pump Inhibitor and an Aspirin Keep the Doctor Away for Patients With Barrettâ€™s Esophagus?. Gastroenterology, 2019, 156, 1228-1231.	1.3	3
75	Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. Gut, 2019, 68, 1918-1927.	12.1	18
76	No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study. Clinical Gastroenterology and Hepatology, 2019, 17, 2227-2235.e1.	4.4	16
77	Barrett's oesophagus and oesophageal adenocarcinoma. Medicine, 2019, 47, 275-285.	0.4	2
78	Feasibility of combined screening for upper gastrointestinal adenocarcinoma risk by serology and Cytosponge testing: the SUGAR study. Journal of Clinical Pathology, 2019, 72, 825-829.	2.0	3
79	The landscape of somatic mutation in normal colorectal epithelial cells. Nature, 2019, 574, 532-537.	27.8	468
80	A Deep Learning Framework for Predicting Response to Therapy in Cancer. Cell Reports, 2019, 29, 3367-3373.e4.	6.4	137
81	A crosssectional analysis of Facebook comments to study public perception of a new diagnostic test called the Cytosponge. Ecological Management and Restoration, 2019, 32, .	0.4	4
82	Acceptability, Accuracy, and Safety of Disposable Transnasal Capsule Endoscopy for Barrett's Esophagus Screening. Clinical Gastroenterology and Hepatology, 2019, 17, 638-646.e1.	4.4	30
83	Safety and Acceptability of Esophageal Cytosponge Cell Collection Device in a Pooled Analysis of Data From Individual Patients. Clinical Gastroenterology and Hepatology, 2019, 17, 647-656.e1.	4.4	54
84	A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma. Ecological Management and Restoration, 2019, 32, .	0.4	26
85	The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. Nature Genetics, 2019, 51, 506-516.	21.4	166
86	Conference report: improving outcomes for gastrointestinal cancer in the UK. Frontline Gastroenterology, 2018, 9, 49-61.	1.8	2
87	Detection of early neoplasia in Barrettâ€™s esophagus using lectin-based near-infrared imaging: an ex vivo study on human tissue. Endoscopy, 2018, 50, 618-625.	1.8	21
88	Determining Risk of Barrettâ€™s Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and GeneticÂVariants. Gastroenterology, 2018, 154, 1273-1281.e3.	1.3	67
89	Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. The Lancet Gastroenterology and Hepatology, 2018, 3, 489-498.	8.1	87
90	New Screening Techniques in Barrettâ€™s Esophagus: Great Ideas or Great Practice?. Gastroenterology, 2018, 154, 1594-1601.	1.3	39

#	Article	IF	Citations
91	Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrettâ€™s Esophagus. Clinical Gastroenterology and Hepatology, 2018, 16, 1598-1606.e4.	4.4	16
92	Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett's oesophagus with low-grade dysplasia. Gut, 2018, 67, 392-393.	12.1	80
93	Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status. Gastrointestinal Endoscopy, 2018, 87, 408-418.	1.0	85
94	Methylation panel is a diagnostic biomarker for Barrettâ€™s oesophagus in endoscopic biopsies and non-endoscopic cytology specimens. Gut, 2018, 67, 1942-1949.	12.1	75
95	Endoscopic Management of Early Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus: Screening, Diagnosis, and Therapy. Gastroenterology, 2018, 154, 421-436.	1.3	182
96	Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts. Gastroenterology, 2018, 155, 1720-1728.e4.	1.3	67
97	Barrettâ€™s oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux. BMC Cancer, 2018, 18, 784.	2.6	37
98	Somatic mutant clones colonize the human esophagus with age. Science, 2018, 362, 911-917.	12.6	805
99	DNA Methylation Biomarkers for the Diagnosis of Barrett's Oesophagus. American Journal of Gastroenterology, 2018, 113, 1722.	0.4	0
100	Organ-preserving approaches in oesophageal cancer. Lancet Oncology, The, 2018, 19, 858-859.	10.7	3
101	Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics. Nature Communications, 2018, 9, 2983.	12.8	206
102	Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. Lancet, The, 2018, 392, 400-408.	13.7	199
103	Screening for Barrettâ€™s Esophagus: Are New High-Volume Methods Feasible?. Digestive Diseases and Sciences, 2018, 63, 2105-2114.	2.3	8
104	Selection and Application of Tissue microRNAs for Nonendoscopic Diagnosis of Barrettâ€™s Esophagus. Gastroenterology, 2018, 155, 771-783.e3.	1.3	38
105	A non-endoscopic device to sample the oesophageal microbiota: a case-control study. The Lancet Gastroenterology and Hepatology, 2017, 2, 32-42.	8.1	111
106	Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. The Lancet Gastroenterology and Hepatology, 2017, 2, 23-31.	8.1	87
107	High-risk individualsâ€™ perceptions of reproductive genetic testing for CDH1 mutations. Familial Cancer, 2017, 16, 531-535.	1.9	7
108	Past, present and future of Barrett's oesophagus. European Journal of Surgical Oncology, 2017, 43, 1148-1160.	1.0	17

#	Article	IF	Citations
109	Evolutionary dynamics in pre-invasive neoplasia. Current Opinion in Systems Biology, 2017, 2, 1-8.	2.6	12
110	Medicine is the ultimate personalised technology. BMJ: British Medical Journal, 2017, 357, j1750.	2.3	0
111	A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy. Genome Research, 2017, 27, 902-912.	5.5	27
112	International cancer seminars: a focus on esophageal squamous cell carcinoma. Annals of Oncology, 2017, 28, 2086-2093.	1.2	149
113	Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. Gut, 2017, 66, 1739-1747.	12.1	38
114	Early Diagnosis of Gastroesophageal Cancers and the Cytosponge: A Work in Progress. Cellular and Molecular Gastroenterology and Hepatology, 2017, 4, 447.	4.5	2
115	Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma. British Journal of Surgery, 2017, 104, 1816-1828.	0.3	88
116	The Evolving Genomic Landscape of Barrettâ€™s Esophagus and Esophageal Adenocarcinoma. Gastroenterology, 2017, 153, 657-673.e1.	1.3	69
117	Oesophageal cancer. Nature Reviews Disease Primers, 2017, 3, 17048.	30.5	671
118	Accuracy and Safety of the Cytosponge for Assessing Histologic Activity in Eosinophilic Esophagitis: A Two-Center Study. American Journal of Gastroenterology, 2017, 112, 1538-1544.	0.4	76
119	Alternatives to Traditional Per-Oral Endoscopy for Screening. Gastrointestinal Endoscopy Clinics of North America, 2017, 27, 379-396.	1.4	12
120	The Psychosocial Impact of Undergoing Prophylactic Total Gastrectomy (PTG) to Manage the Risk of Hereditary Diffuse Gastric Cancer (HDGC). Journal of Genetic Counseling, 2017, 26, 752-762.	1.6	29
121	Range of pathologies diagnosed using a minimally invasive capsule sponge to evaluate patients with reflux symptoms. Histopathology, 2017, 70, 203-210.	2.9	45
122	Application of a multiâ€gene nextâ€generation sequencing panel to a nonâ€invasive oesophageal cellâ€sampling device to diagnose dysplastic Barrett's oesophagus. Journal of Pathology: Clinical Research, 2017, 3, 258-267.	3.0	8
123	Open chromatin profiling identifies AP1 as a transcriptional regulator in oesophageal adenocarcinoma. PLoS Genetics, 2017, 13, e1006879.	3.5	41
124	Decision making, quality of life and prophylactic gastrectomy in carriers of pathogenic CDH1 mutations. Translational Gastroenterology and Hepatology, 2017, 2, 21-21.	3.0	4
125	Impact of mutations in Toll-like receptor pathway genes on esophageal carcinogenesis. PLoS Genetics, 2017, 13, e1006808.	3.5	19
126	Polymorphisms in genes in the androgen pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. International Journal of Cancer, 2016, 138, 1146-1152.	5.1	10

#	Article	IF	Citations
127	The Discovery and Validation of Biomarkers for the Diagnosis of Esophageal Squamous Dysplasia and Squamous Cell Carcinoma. Cancer Prevention Research, 2016, 9, 558-566.	1.5	24
128	Leadership roles for women in gastroenterology: New initiatives for the new generation of gastroenterologists. United European Gastroenterology Journal, 2016, 4, 815-815.	3.8	1
129	A multicentre cohort study to redefine and validate pathological assessment of response to neoadjuvant therapy in treated oesophagogastric adenocarcinoma. European Journal of Surgical Oncology, 2016, 42, S252.	1.0	1
130	Signatures of Mutational Processes and Associated Risk Factors in Esophageal Squamous Cell Carcinoma: A Geographically Independent Stratification Strategy?. Gastroenterology, 2016, 150, 1080-1083.	1.3	3
131	Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nature Genetics, 2016, 48, 1131-1141.	21.4	332
132	Design and validation of a near-infrared fluorescence endoscope for detection of early esophageal malignancy. Journal of Biomedical Optics, 2016, 21, 084001.	2.6	23
133	Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. Lancet Oncology, The, 2016, 17, 1363-1373.	10.7	133
134	Genetic progression of Barrettâ€™s oesophagus to oesophageal adenocarcinoma. British Journal of Cancer, 2016, 115, 403-410.	6.4	49
135	Genomics of Esophageal Cancer and Biomarkers for Early Detection. Advances in Experimental Medicine and Biology, 2016, 908, 237-263.	1.6	6
136	Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1. Scientific Reports, 2016, 6, 32417.	3.3	20
137	An investigation of the factors effecting high-risk individualsâ€™ decision-making about prophylactic total gastrectomy and surveillance for hereditary diffuse gastric cancer (HDGC). Familial Cancer, 2016, 15, 665-676.	1.9	28
138	Pilot randomized crossover study comparing the efficacy of transnasal disposable endosheath with standard endoscopy to detect Barrettâ€™s esophagus. Endoscopy, 2016, 48, 110-116.	1.8	34
139	Whole-genome sequencing of nine esophageal adenocarcinoma cell lines. F1000Research, 2016, 5, 1336.	1.6	23
140	Genetics and Biomarkers in Barrettâ€™s Esophagus and Esophageal Adenocarcinoma. , 2016, , 37-60.		0
141	MiRNA-Related SNPs and Risk of Esophageal Adenocarcinoma and Barrettâ€™s Esophagus: Post Genome-Wide Association Analysis in the BEACON Consortium. PLoS ONE, 2015, 10, e0128617.	2.5	21
142	Polymorphisms in Genes of Relevance for Oestrogen and Oxytocin Pathways and Risk of Barrettâ€™s Oesophagus and Oesophageal Adenocarcinoma: A Pooled Analysis from the BEACON Consortium. PLoS ONE, 2015, 10, e0138738.	2.5	9
143	Polymorphisms Near TBX5 and GDF7 Are Associated With Increased Risk for Barrettâ€™s Esophagus. Gastroenterology, 2015, 148, 367-378.	1.3	93
144	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germlineCDH1mutation carriers. Journal of Medical Genetics, 2015, 52, 361-374.	3.2	479

#	Article	IF	Citations
145	Evaluation of a Minimally Invasive Cell Sampling Device Coupled with Assessment of Trefoil Factor 3 Expression for Diagnosing Barrett's Esophagus: A Multi-Center Caseâ€“Control Study. PLoS Medicine, 2015, 12, e1001780.	8.4	212
146	The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett's oesophagus. Gut, 2015, 64, 49-56.	12.1	60
147	Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nature Genetics, 2015, 47, 1038-1046.	21.4	262
148	54 Evaluation of a Minimally-Invasive Cytosponge Esophageal Cell Collection System in Patients With Barrett's Esophagus. Gastroenterology, 2015, 148, S-16.	1.3	6
149	Screening for Barrettâ€™s Esophagus. Gastroenterology, 2015, 148, 912-923.	1.3	54
150	Combining simple patientâ€oriented tests with stateâ€ofâ€theâ€art molecular diagnostics for early diagnosis of cancer. United European Gastroenterology Journal, 2015, 3, 226-229.	3.8	6
151	Biomarkers in Barrettâ€™s Esophagus. Gastroenterology Clinics of North America, 2015, 44, 373-390.	2.2	18
152	Precision prevention of oesophageal adenocarcinoma. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 243-248.	17.8	129
153	Analysis of Dysplasia in Patients With Barrettâ€™s Esophagus Based on Expression Pattern of 90 Genes. Gastroenterology, 2015, 149, 1511-1518.e5.	1.3	25
154	Autofluorescence-Directed Confocal Endomicroscopy in Combination With a Three-Biomarker Panel Can Inform Management Decisions in Barrettâ€™s Esophagus. American Journal of Gastroenterology, 2015, 110, 1549-1558.	0.4	24
155	Mobile element insertions are frequent in oesophageal adenocarcinomas and can mislead paired-end sequencing analysis. BMC Genomics, 2015, 16, 473.	2.8	21
156	Accuracy, Safety, and Tolerability of Tissue Collection by Cytosponge vs Endoscopy for Evaluation of Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2015, 13, 77-83.e2.	4.4	132
157	Biomarkers for Dysplastic Barrettâ€™s: Ready for Prime Time?. World Journal of Surgery, 2015, 39, 568-577.	1.6	10
158	Screening for Barrett Esophagus With a Nonendoscopic Sponge Capsule. Gastroenterology and Hepatology, 2015, 11, 623-5.	0.1	1
159	Amplification of TRIM44: Pairing a Prognostic Target With Potential Therapeutic Strategy. Journal of the National Cancer Institute, 2014, 106, .	6.3	38
160	Pilot study of cytological testing for oesophageal squamous cell dysplasia in a high-risk area in Northern Iran. British Journal of Cancer, 2014, 111, 2235-2241.	6.4	35
161	The Impact of Prophylactic Total Gastrectomy on Health-Related Quality of Life. Annals of Surgery, 2014, 260, 87-93.	4.2	44
162	Targeting care in Barrettâ€™s oesophagus. Clinical Medicine, 2014, 14, s78-s83.	1.9	10

#	Article	IF	Citations
163	Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance. Gastrointestinal Endoscopy, 2014, 80, 78-87.	1.0	75
164	Body Mass Index, Smoking, and Alcohol and Risks of Barrettâ€™s Esophagus and Esophageal Adenocarcinoma: A UK Prospective Cohort Study. Digestive Diseases and Sciences, 2014, 59, 1552-1559.	2.3	38
165	British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut, 2014, 63, 7-42.	12.1	1,116
166	Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. Carcinogenesis, 2014, 35, 2740-2747.	2.8	31
167	Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nature Genetics, 2014, 46, 837-843.	21.4	302
168	Gastro-Esophageal Reflux Disease Symptoms and Demographic Factors as a Pre-Screening Tool for Barrettâ€™s Esophagus. PLoS ONE, 2014, 9, e94163.	2.5	27
169	A review of the current understanding and clinical utility of miRNAs in esophageal cancer. Seminars in Cancer Biology, 2013, 23, 512-521.	9.6	104
170	1004 Radiofrequency Ablation in Barrett's Esophagus With Confirmed Low-Grade Dysplasia: Interim Results of a European Multicenter Randomized Controlled Trial (SURF). Gastroenterology, 2013, 144, S-187.	1.3	10
171	Screening and Risk Stratification for Barrett's Esophagus. Gastroenterology Clinics of North America, 2013, 42, 155-173.	2.2	16
172	Health Benefits and Cost Effectiveness of Endoscopic and Nonendoscopic Cytosponge Screening for Barrett's Esophagus. Gastroenterology, 2013, 144, 62-73.e6.	1.3	146
173	A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nature Genetics, 2013, 45, 1487-1493.	21.4	174
174	DNA Methylation as an Adjunct to Histopathology to Detect Prevalent, Inconspicuous Dysplasia and Early-Stage Neoplasia in Barrett's Esophagus. Clinical Cancer Research, 2013, 19, 878-888.	7.0	65
175	Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis. Journal of Pathology, 2013, 230, 118-128.	4.5	35
176	Three-Gene Immunohistochemical Panel Adds to Clinical Staging Algorithms to Predict Prognosis for Patients With Esophageal Adenocarcinoma. Journal of Clinical Oncology, 2013, 31, 1576-1582.	1.6	66
177	Screening for oesophageal cancer. Nature Reviews Clinical Oncology, 2012, 9, 278-287.	27.6	124
178	Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. Nature Medicine, 2012, 18, 315-321.	30.7	285
179	Identification and Clinical Implementation of Biomarkers for Barrett's Esophagus. Gastroenterology, 2012, 142, 435-441.e2.	1.3	45
180	Population-Based Study Reveals New Risk-Stratification Biomarker Panel for Barrett's Esophagus. Gastroenterology, 2012, 143, 927-935.e3.	1.3	151

#	Article	IF	Citations
181	Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett's esophagus. Gastrointestinal Endoscopy, 2012, 75, 954-961.	1.0	105
182	958 Time: A Prospective Study Combining Endoscopic Trimodal Imaging and Molecular Endpoints to Improve Risk Stratification in Barrett's Esophagus. Gastroenterology, 2012, 142, S-165.	1.3	6
183	Evidence for a functional role of epigenetically regulated midclusterHOXBgenes in the development of Barrett esophagus. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9077-9082.	7.1	62
184	Developing a nonendoscopic screening test for Barrettâ€™s esophagus. Biomarkers in Medicine, 2011, 5, 397-404.	1.4	35
185	Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ: British Medical Journal, 2010, 341, c4372-c4372.	2.3	271
186	Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2177-2182.	7.1	143
187	History, Molecular Mechanisms, and Endoscopic Treatment of Barrett's Esophagus. Gastroenterology, 2010, 138, 854-869.	1.3	181
188	A 4-Gene Signature Predicts Survival of Patients With Resected Adenocarcinoma of the Esophagus, Junction, and Gastric Cardia. Gastroenterology, 2010, 139, 1995-2004.e15.	1.3	135
189	Abstract 1189: Chromosomal aberrations reveal novel genes with prognostic significance in esophageal adenocarcinoma. , 2010, , .		0
190	Progressive silencing of p14ARF in oesophageal adenocarcinoma. Journal of Cellular and Molecular Medicine, 2009, 13, 398-409.	3.6	14
191	Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. Gut, 2009, 58, 1451-1459.	12.1	104
192	Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk. Journal of Pathology, 2008, 216, 286-294.	4.5	108
193	Mechanisms and sequelae of Eâ€cadherin silencing in hereditary diffuse gastric cancer. Journal of Pathology, 2008, 216, 295-306.	4.5	122
194	Non-endoscopic immunocytological screening test for Barrett's oesophagus. Gut, 2007, 56, 1033-1034.	12.1	20
195	Cyclin A Immunocytology as a Risk Stratification Tool for Barrett's Esophagus Surveillance. Clinical Cancer Research, 2007, 13, 659-665.	7.0	65
196	Nitric Oxide and Acid Induce Double-Strand DNA Breaks in Barrettâ€™s Esophagus Carcinogenesis via Distinct Mechanisms. Gastroenterology, 2007, 133, 1198-1209.	1.3	94
197	Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut, 2006, 55, 1810-1820.	12.1	118
198	Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?. Gut, 2005, 54, i21-i26.	12.1	59

#	Article	IF	Citations
199	Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. Gut, 2004, 53, 775-778.	12.1	84
200	Review article: Barrett's oesophagus and associated adenocarcinoma - a UK perspective. Alimentary Pharmacology and Therapeutics, 2004, 20, 45-49.	3.7	24
201	Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus. Clinical Cancer Research, 2003, 9, 2560-6.	7.0	74
202	Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut, 2002, 50, 451-459.	12.1	229
203	National clinician scientist posts. BMJ: British Medical Journal, 2002, 325, 101S-101.	2.3	0
204	Women in hospital medicine: career choices and opportunities. British Journal of Hospital Medicine, 2001, 62, 778-779.	0.2	5
205	Barrettâ€™s oesophagus, dysplasia and pharmacologic acid suppression. Alimentary Pharmacology and Therapeutics, 2001, 15, 269-276.	3.7	47
206	Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. Digestive Diseases and Sciences, 2001, 46, 1892-1898.	2.3	106
207	Altered sodium-hydrogen exchange activity is a mechanism for acid-induced hyperproliferation in Barrettâ€™s esophagus. American Journal of Physiology - Renal Physiology, 1998, 275, G47-G55.	3.4	47
208	Acid modulation of HT29 cell growth and differentiation An in vitro model for Barrettâ€™s esophagus. Journal of Cell Science, 1997, 110, 663-671.	2.0	60
209	Testosterone concentrations in men on chronic glucocorticosteroid therapy. Journal of the Royal College of Physicians of London, 1997, 31, 168-70.	0.2	9
210	Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model.. Journal of Clinical Investigation, 1996, 98, 2120-2128.	8.2	298
211	Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction. Gut, 0, , gutjnl-2022-327281.	12.1	13
212	eQTL set-based association analysis identifies novel susceptibility loci for Barrett's esophagus and esophageal adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 0, , .	2.5	1